This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, National Institute of Health and Medical Research, University Joseph Fourier (Grenoble 1). Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2015
Title: Innovations of Alexandre Bougdour
Introduction
Alexandre Bougdour is a notable inventor based in Grenoble, France. He has made significant contributions to the field of cyclic peptides, particularly in their application as anti-parasitic and anticancer agents. His work has implications for both medical treatments and organ transplantation.
Latest Patents
One of Bougdour's key patents is focused on cyclic peptides with anti-parasitic activity. The invention details a method for preparing these cyclic peptides, which can be utilized in the treatment of conditions such as toxoplasmosis. Additionally, the cyclic peptide has potential applications as an anticancer agent and can be used for treating organs ex vivo before transplantation. This patent highlights the innovative approach Bougdour has taken in addressing critical health issues.
Career Highlights
Throughout his career, Bougdour has been associated with prestigious institutions such as the University Joseph Fourier (Grenoble 1) and the Centre National de la Recherche Scientifique. His work in these organizations has allowed him to advance his research and collaborate with other experts in the field.
Collaborations
Some of Bougdour's notable coworkers include Yung-Sing Wong and Mohamed-Ali Hakimi. Their collaborative efforts have contributed to the development of innovative solutions in the realm of cyclic peptides.
Conclusion
Alexandre Bougdour's contributions to the field of cyclic peptides demonstrate his commitment to advancing medical science. His innovative patent and collaborations with esteemed colleagues reflect his significant impact on research and development in this area.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile